The US Food and Drug Administration (FDA) has approved a new kind of blood thinner to help prevent repeat strokes. Sunharbo (asundexian), a once-daily tablet, is the first medicine approved in the US that works by blocking factor XIa, a protein involved in forming harmful blood clots. The approval, announced on 9 November 2026, covers adults who have had a recent mild to moderate stroke, or a high-risk mini-stroke, and it is taken together with antiplatelet therapy.
Who Sunharbo Is For
Sunharbo is approved for adults after a recent mild to moderate non-cardioembolic ischaemic stroke, a stroke caused by a clot that did not originate in the heart, or a high-risk transient ischaemic attack (TIA), often called a mini-stroke. It is a 50 mg tablet taken once a day, alongside antiplatelet therapy. The FDA granted the medicine Fast Track and Priority Review designations, and the approval was granted to Bayer HealthCare Pharmaceuticals Inc. of Whippany, New Jersey.
The approval has clear boundaries. Sunharbo is not approved for stroke prevention in patients with atrial fibrillation, a heart rhythm condition that carries its own stroke risk and its own approved treatments. It is also not recommended in patients with moderate or severe liver impairment, and it should not be taken with medicines that are combined P-gp and strong CYP3A4 inducers, such as carbamazepine, because those medicines may reduce its effectiveness. It should be stopped at least 24 hours before elective surgery or invasive procedures, and for at least 24 hours after thrombolysis for acute ischaemic stroke.
What the OCEANIC-STROKE Trial Showed
The approval rests on the OCEANIC-STROKE study, a multicentre, randomised, double-blind, placebo-controlled phase 3 trial that enrolled 12,327 adults at 702 centres in 37 countries. Participants had a recent non-cardioembolic ischaemic stroke, with a National Institutes of Health Stroke Scale score of 15 or less, or a high-risk TIA, and were randomly assigned to Sunharbo or placebo within 72 hours of symptom onset. Both groups also received antiplatelet therapy. The results were published in the New England Journal of Medicine in 2026.
Sunharbo 50 mg once daily reduced the risk of ischaemic stroke by 26% compared with placebo over a median treatment of 14.2 months. On safety, the overall rate of major bleeding was similar between the Sunharbo and placebo groups, but it was higher with Sunharbo in patients older than 75 and during the first 90 days of treatment. Gastrointestinal bleeding occurred more commonly with Sunharbo, and the most frequently reported adverse reaction was diarrhoea, in 3% or more of patients taking the medicine.
"Stroke is a leading cause of disability and death in the United States, and survivors are at risk of having another stroke," said Hylton V. Joffe, MD, MMSc, Director of the Office of Cardiology, Hematology, Endocrinology, and Nephrology in the FDA's Center for Drug Evaluation and Research. "Today's approval represents a meaningful advance for patients and health care providers seeking a new option for secondary stroke prevention."
Why This Matters for Healthcare Organizations
For hospitals and clinics that care for stroke survivors, a new secondary prevention option matters because the risk after a first stroke is high and the choices have been narrow. Existing blood thinners such as Eliquis and Xarelto work by blocking factor Xa, a different clotting protein, and the new medicine targets a different step in the clotting process. That gives clinicians another option for patients whose stroke was not caused by a clot from the heart, which is the population the trial studied.
The practical details deserve as much attention as the headline result. The higher bleeding risk in patients older than 75 and in the first 90 days means age and timing should shape the decision, and the list of medicines to avoid and the rules on stopping before surgery need to reach the prescribing and pharmacy teams. The atrial fibrillation exclusion is also important: a patient whose stroke came from a heart clot is not a candidate, and that distinction needs to be clear in the record before the medicine is started.
Analysis: A New Mechanism, With Careful Boundaries
Sunharbo is the first approval in a class that drug developers have pursued for years, and the reason is the trade-off it promises: preventing harmful clots while leaving normal clotting largely alone. The trial results support that idea in part. A 26% reduction in ischaemic stroke with no overall increase in major bleeding is a real result, and it is why the FDA moved quickly with Fast Track and Priority Review.
The limits in the label show where the promise has not yet been proven. The higher bleeding in older patients and early treatment, the exclusion of atrial fibrillation, and the interaction and liver warnings all narrow the population. The next question is how the medicine performs outside a trial, in older and sicker patients and in routine practice, where the boundaries the FDA drew will be tested every day.
Clinics reviewing how patient communication and follow-up work can be handled can explore MedClinicX's AI patient portal, see how after-hours calls are handled on our AI medical receptionist page, or explore the demos and request a quote. For related coverage, see our earlier articles on the FDA granting accelerated approval to Voceryq, the first plasmid DNA immunotherapy for a rare airway disease and the FDA granting accelerated approval to Rybrevant Faspro for advanced head and neck cancer.
Sources and References
- U.S. Food and Drug Administration, FDA Approves First Factor XIa Inhibitor to Help Prevent Stroke in Certain Adults at High Risk, press announcement, 9 November 2026: https://www.fda.gov/news-events/press-announcements/fda-approves-first-factor-xla-inhibitor-help-prevent-stroke-certain-adults-high-risk
- Reuters, via SRN News, US FDA approves Bayer's blood thinner to prevent repeat strokes, 9 November 2026: https://srnnews.com/us-fda-approves-bayers-blood-thinner-to-prevent-repeat-strokes/
- NeurologyLive, FDA Approves Factor XIa Inhibitor Asundexian for Secondary Stroke Prevention, 9 November 2026: https://www.neurologylive.com/view/fda-approves-asundexian-treatment-secondary-stroke-prevention
- Sharma M et al., Asundexian for secondary stroke prevention, New England Journal of Medicine, 2026;394(15):1467-1479, as cited by HCPLive and the FDA: https://www.nejm.org/doi/full/10.1056/NEJMoa2513880
Reporting based on the sources above, accessed 10 November 2026. The FDA press announcement was read directly, and the Reuters and NeurologyLive reports were read directly and cross-checked against it. MedClinicX did not conduct original reporting or interviews for this article. Corrections: contact us via https://medclinicx.com/contact